Biopharmaceutical Company Announces Presents Preclinical Data For Netherton Syndrome Treatment

Azitra, Inc., a company in the field of clinical-stage biopharmaceuticals dedicated to pioneering precision dermatology, is at the horizon of an exciting development in the treatment of Netherton Syndrome. On May 10, 2024, during the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Baltimore, MD, Azitra unveiled its latest achievement—significant preclinical data concerning ATR-12, a promising candidate in its robust pipeline. $Azitra(AZTR.US)$